1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Neuroprotection Market, by Product
6.1. Introduction
6.2. Apoptosis Inhibitors
6.3. Free Anti-Inflammatory Agents
6.4. Glutamate Antagonists
6.5. Metal Ion Chelators
6.6. Neurotrophic Factors
6.7. Radical Trapping Agents
6.8. Stimulants

7. Neuroprotection Market, by Treatment
7.1. Introduction
7.2. Alzheimer's disease
7.3. Amyotrophic lateral sclerosis
7.4. Brain injury
7.5. Huntington's disease
7.6. Multiple sclerosis
7.7. Neuropathies
7.8. Ocular degeneration
7.9. Parkinson's disease

8. Neuroprotection Market, by Application
8.1. Introduction
8.2. Prevention
8.3. Treatment

9. California Neuroprotection Market

10. Florida Neuroprotection Market

11. Illinois Neuroprotection Market

12. New York Neuroprotection Market

13. Ohio Neuroprotection Market

14. Pennsylvania Neuroprotection Market

15. Texas Neuroprotection Market

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. AbbVie Inc.
17.2. Allergan plc
17.3. Allon therapeutics, Inc.
17.4. AstraZeneca plc
17.5. Astrocyte Pharmaceuticals, Inc.
17.6. Bayer Healthcare, Eisai Inc.
17.7. Bio Vision Inc.
17.8. Biogen Inc.
17.9. Bionure Inc.
17.10. Ceregene, BHRPharma LLC
17.11. Daiichi Sankyo Company
17.12. Dr. Reddy's Laboratories Ltd.
17.13. Eisai Inc.
17.14. Eli Lilly and Company
17.15. Genervon Biopharmaceuticals
17.16. GlaxoSmithKline Plc
17.17. Hoffmann-La Roche AG
17.18. Merck KGaA
17.19. Neuren Pharmaceuticals
17.20. NeuroVive Pharmaceutical
17.21. Novartis AG
17.22. Serono S.A.
17.23. Teva Pharmaceutical Industries Ltd.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES NEUROPROTECTION MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEUROPROTECTION MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2027
FIGURE 6. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, 2018-2027 (USD MILLION)
FIGURE 11. UNITED STATES NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 12. UNITED STATES NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 14. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 16. UNITED STATES NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, 2018-2027 (USD MILLION)
FIGURE 17. UNITED STATES NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 18. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STIMULANTS, 2018-2027 (USD MILLION)
FIGURE 19. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STIMULANTS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 20. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2020 VS 2027 (%)
FIGURE 21. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2020 VS 2027 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2027
FIGURE 23. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, 2018-2027 (USD MILLION)
FIGURE 26. UNITED STATES NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 27. UNITED STATES NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, 2018-2027 (USD MILLION)
FIGURE 28. UNITED STATES NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 29. UNITED STATES NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, 2018-2027 (USD MILLION)
FIGURE 30. UNITED STATES NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 31. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2027 (USD MILLION)
FIGURE 32. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 33. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, 2018-2027 (USD MILLION)
FIGURE 34. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 35. UNITED STATES NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, 2018-2027 (USD MILLION)
FIGURE 36. UNITED STATES NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 37. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2027 (USD MILLION)
FIGURE 38. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 39. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2020 VS 2027 (%)
FIGURE 40. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2020 VS 2027 (USD MILLION)
FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2027
FIGURE 42. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PREVENTION, 2018-2027 (USD MILLION)
FIGURE 43. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PREVENTION, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 44. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
FIGURE 45. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 46. UNITED STATES NEUROPROTECTION MARKET: FPNV POSITIONING MATRIX
FIGURE 47. UNITED STATES NEUROPROTECTION MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES NEUROPROTECTION MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES NEUROPROTECTION MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY STATE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STIMULANTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, BY STATE, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PREVENTION, BY STATE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES NEUROPROTECTION MARKET: SCORES
TABLE 24. UNITED STATES NEUROPROTECTION MARKET: BUSINESS STRATEGY
TABLE 25. UNITED STATES NEUROPROTECTION MARKET: PRODUCT SATISFACTION
TABLE 26. UNITED STATES NEUROPROTECTION MARKET: RANKING
TABLE 27. UNITED STATES NEUROPROTECTION MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 28. UNITED STATES NEUROPROTECTION MARKET: MERGER & ACQUISITION
TABLE 29. UNITED STATES NEUROPROTECTION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 30. UNITED STATES NEUROPROTECTION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 31. UNITED STATES NEUROPROTECTION MARKET: INVESTMENT & FUNDING
TABLE 32. UNITED STATES NEUROPROTECTION MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 33. UNITED STATES NEUROPROTECTION MARKET: LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
Allergan plc
Allon therapeutics, Inc.
AstraZeneca plc
Astrocyte Pharmaceuticals, Inc.
Bayer Healthcare, Eisai Inc.
Bio Vision Inc.
Biogen Inc.
Bionure Inc.
Ceregene, BHRPharma LLC
Daiichi Sankyo Company
Dr. Reddy's Laboratories Ltd.
Eisai Inc.
Eli Lilly and Company
Genervon Biopharmaceuticals
GlaxoSmithKline Plc
Hoffmann-La Roche AG
Merck KGaA
Neuren Pharmaceuticals
NeuroVive Pharmaceutical
Novartis AG
Serono S.A.
Teva Pharmaceutical Industries Ltd.